Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.12USD
1:30pm EST
Change (% chg)

$0.03 (+1.19%)
Prev Close
$2.10
Open
$2.15
Day's High
$2.15
Day's Low
$2.10
Volume
14,461
Avg. Vol
218,656
52-wk High
$5.75
52-wk Low
$1.58

Chart for

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 2.96
Market Cap(Mil.): $105.71
Shares Outstanding(Mil.): 50.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share

* Acelrx pharmaceuticals reports third quarter 2017 financial results

Nov 09 2017

AcelRx Pharma shares sink as FDA rejects opioid painkiller

Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

Oct 12 2017

UPDATE 4-AcelRx Pharma shares sink as FDA rejects opioid painkiller

* Shares tumble as much as 62.6 pct to $2.00 (Adds CEO comments)

Oct 12 2017

BRIEF-AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA

* AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA

Oct 12 2017

FDA rejects AcelRx Pharma's pain drug

Oct 12 U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday.

Oct 12 2017

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

Aug 23 2017

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

Aug 01 2017

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

Aug 01 2017

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

Jul 19 2017

Earnings vs. Estimates